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A B S T R A C T
Germline mutations in SAMD9 and SAMD9L genes cause MIRAGE (myelodysplasia, infection, restriction of growth,
adrenal hypoplasia, genital phenotypes, and enteropathy) (OMIM: *610456) and ataxia-pancytopenia (OMIM:
*611170) syndromes, respectively, and are associated with chromosome 7 deletions, myelodysplastic syndrome
(MDS), and bone marrow failure. In this retrospective series, we report outcomes of allogeneic hematopoietic cell
transplantation (HCT) in patients with hematologic disorders associated with SAMD9/SAMD9L mutations. Twelve
patients underwent allogeneic HCT for MDS (n = 10), congenital amegakaryocytic thrombocytopenia (n = 1), and
dyskeratosis congenita (n = 1). Exome sequencing revealed heterozygous mutations in SAMD9 (n = 6) or SAMD9L
(n = 6) genes. Four SAMD9 patients had features of MIRAGE syndrome. Median age at HCT was 2.8 years (range,
1.2 to 12.8 years). Conditioning was myeloablative in 9 cases and reduced intensity in 3 cases. Syndrome-related
comorbidities (diarrhea, infections, adrenal insufﬁciency, malnutrition, and electrolyte imbalance) were present
in MIRAGE syndrome cases. One patient with a familial SAMD9L mutation, MDS, and morbid obesity failed to
engraft and died of refractory acute myeloid leukemia. The other 11 patients achieved neutrophil engraftment.
Acute post-transplant course was complicated by syndrome-related comorbidities in MIRAGE cases. A patient
with SAMD9L-associated MDS died of diffuse alveolar hemorrhage. The other 10 patients had resolution of hematologic disorder and sustained peripheral blood donor chimerism. Ten of 12 patients were alive with a median
follow-up of 3.1 years (range, 0.1 to 14.7 years). More data are needed to reﬁne transplant approaches in SAMD9/
SAMD9L patients with signiﬁcant comorbidities and to develop guidelines for their long-term follow-up.
© 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

INTRODUCTION
In recent years, advances in genetic interrogation of patient
samples have led to discovery of several novel genes that
underlie inherited bone marrow failure and myelodysplastic
syndrome (MDS) [1]. These include SAMD9 (sterile a-motif
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domain-containing protein 9) and SAMD9L (SAMD9-like)
genes, located head to tail on chromosome 7q21.2 in a region
that is frequently deleted in myeloid malignancies [2,3].
Germline mutations in SAMD9 and SAMD9L cause the multisystem disorders, MIRAGE (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and
enteropathy) and ataxia-pancytopenia syndromes, respectively [4-6]. Recent studies in children reported a rate of
SAMD9 and SAMD9L mutations in 18.6% and 17% cases with
suspected inherited bone marrow failure syndromes and those
with primary MDS, respectively [7,8].

https://doi.org/10.1016/j.bbmt.2019.07.007
1083-8791/© 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
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SAMD9 and SAMD9L proteins are involved in endosomal trafﬁcking and negatively regulate cell proliferation [9]. Gain-of-function heterozygous mutations in these genes lead to cellular
growth restriction and hypoplasia, resulting in cytopenias, bone
marrow failure, and immunodeﬁciency. Interestingly, in many
cases, there is a nonrandom loss of the mutated allele via full or
partial deletion of chromosome 7 [4,10-12]. The resultant monosomy 7 or deletion 7q can result in the development of MDS and
acute myeloid leukemia (AML) [8,11,12]. Conversely, other
“genetic correction” events such as in cis missense, nonsense, or
loss of heterozygosity through uniparental disomy can result in
normal hematopoiesis.
Since the initial report of MIRAGE syndrome in 2016, a
series of studies has described clinical and genetic ﬁndings in
patients and families with SAMD9/SAMD9L mutations
[7,11,13]. Hematopoietic cell transplantation (HCT) therapy
has been included in some reports, but transplantation details
are lacking. A recent article by Sarthy et al. [14] documented 2
children with MIRAGE syndrome who succumbed to posttransplant complications due to syndrome-related comorbidities. We aimed to obtain a more complete assessment of
transplant outcomes and the challenges and complications
encountered in these patients.
METHODS
After management of 2 cases with MIRAGE syndrome, additional cases
were identiﬁed by literature search and peer consultations. For inclusion,
patients were required to have a conﬁrmed heterozygous mutation in the
SAMD9 or SAMD9L gene and a minimum of 1-year follow-up post-transplant.
Deidentiﬁed data for each case were collected by using a standardized questionnaire. All studies involving human subjects were performed in accordance with site-speciﬁc protocols approved by the institutional review board
and in accordance with Declaration of Helsinki guidelines.
The primary study endpoints were overall survival and event-free survival.
Safety and tolerability of HCT and impact of pretransplant comorbidities were
evaluated by occurrence and severity of post-transplant complications, need for
life support measures, and risk of transplant-related mortality. Transplant outcomes were deﬁned using Center for International Blood and Marrow Transplant Research criteria [15]. Grading of acute graft-versus-host disease (GVHD)
and diagnosis of chronic GVHD were based on standard criteria [16]. Surviving
patients were censored at last follow-up. Continuous variables were summarized as median and range of values and analyzed using the Mann-Whitney test.
Survival curves were generated using the Kaplan-Meier method and compared
using the log-rank (Mantel-Cox) test using the GraphPad Prism 7 software
(GraphPad Software, San Diego, CA).

RESULTS
Twelve patients underwent allogeneic HCT for hematologic
disorders associated with germline SAMD9 (n = 6) or SAMD9L
(n = 6) mutations (Table 1). Patients 3, 4, 6, 11, and 12 (Table 1)
were included in previous reports [11,13,17]. Indication for transplant was MDS in 10 of 12 (83%) cases. One SAMD9 patient with
markedly reduced megakaryocytic precursors in marrow underwent transplantation for a presumed diagnosis of congenital
amegakaryocytic thrombocytopenia, and 1 patient with SAMD9L
mutation and shortened telomeres underwent transplantation
on a presumed diagnosis of dyskeratosis congenita.
Median age at presentation for patients with SAMD9 mutations (1.65 years; range, 0.17 to 4.8 years) was similar to those
with SAMD9L mutations (1.43 years; range, 0.67 to 12.6 years).
Six patients had pancytopenia, including 5 with thrombocytopenia and 1 with anemia. Bone marrow was hypocellular in 11
(92%) cases and showed dysplasia most prominently in the
megakaryocytic lineage in most cases. Chromosome 7 abnormalities, including monosomy 7 and chromosome 7q deletions, were present in all cases. All except 1 case showed
somatic mosaicism for chromosome 7 abnormalities (ie, detection of a monosomy 7 or chromosome 7 deletion clone in only
a fraction of hematopoietic cells in bone marrow).
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Exome sequencing revealed 5 different missense heterozygous mutations in the 6 SAMD9 cases and 4 different missense
mutations in the 6 SAMD9L cases. Their genomic details and
pathogenicity assessment of variants are summarized in
Table 2 and cross-referenced [5,7,8,12,13,17-20]. Six of 12
cases were familial. Four SAMD9 patients had phenotypic features of MIRAGE syndrome (patients 1, 2, 5, and 6; Tables 1
and 2); unique ﬁndings included panhypopituitarism, laryngeal cleft, and glomerulosclerosis. Two other cases with a
SAMD9 mutation had milder phenotypes with growth restriction in 1 and hypospadias and a biﬁd scrotum in another. The
remaining patients had no phenotypic abnormalities.
Transplant details of individual cases are summarized in
Table 3. Median age at HCT was 2.8 years (range, 1.16 to 12.8
years). Median age at HCT tended to be higher in SAMD9
patients versus SAMD9L patients at 4.15 years versus 2.2 years,
respectively (P = .81). Median time from initial presentation to
transplant was 0.45 years (range, 0.2 to 6.53 years). There was
an interval of 5.5 and 6.53 years from initial diagnosis to HCT
in 2 cases of MIRAGE syndrome because in these cases, blood
counts seemed to show improvement before patients developed sustained marrow failure. Stem cell sources included
bone marrow (matched unrelated, n = 7; HLA identical sibling,
n = 2; and haploidentical parent, n = 1) and unrelated cord
blood (n = 2). Nine patients received myeloablative conditioning (busulfan based, n = 7, or total-body irradiation based,
n = 2). Three patients received reduced-intensity conditioning
with ﬂudarabine, cyclophosphamide, or melphalan, with rabbit antithymocyte globulin or alemtuzumab.
Clinically signiﬁcant pretransplant comorbidities were present
in SAMD9 cases with MIRAGE syndrome (Table 3). These included
chronic diarrhea, electrolyte imbalance, infections, adrenal insufﬁciency, failure to thrive, lung disease, and renal dysfunction. One
patient with SAMD9L mutation (patient 10, Table 2 and Table 3)
had been treated for hemophagocytic lymphohistiocytosis, disseminated sepsis, invasive fungal infections before transplant.
Post-transplant complications included pericardial effusions
(n = 3), veno-occlusive disease of liver (n = 3), thrombotic microangiopathy (n = 2), and diffuse alveolar hemorrhage (n = 1).
Unique complications in several MIRAGE syndrome cases
included large volume stool losses with dehydration and electrolyte imbalance, temperature and blood pressure instability, and
hypoxia. Eight patients required transfer to intensive care for
management of respiratory failure (n = 5), sepsis (n = 1), and
severe hypertension (n = 1) and VOD of liver (n = 1).
One patient with a familial SAMD9L mutation, MDS,
(patient 7, Table 3) and morbid obesity failed to engraft following reduced-intensity conditioning with double unrelated cord
blood transplantation. All other patients achieved neutrophil
and platelet engraftment at a median of 16 days (range, 12 to
19; n = 11) and 17 days (range, 12 to 40; n = 10) post-HCT,
respectively. Two patients developed grade II to III acute
GVHD, which resolved with treatment. Two patients developed mild skin chronic GVHD. Two patients have chronic lung
disease, and 2 other patients have chronic kidney disease. One
patient with SAMD9L mutation and MDS (patient 7, Table 3)
with failed engraftment subsequently developed AML and
died of its treatment complications. A second patient, with
SAMD9L mutation and MDS (patient 10, Table 3), died of diffuse alveolar hemorrhage while receiving deﬁbrotide for treatment of veno-occlusive disease of liver. Immune
reconstitution data are summarized in Table 4.
Ten of 12 patients were alive with a median follow-up of
3.1 years (range, 0.1 to 14.7 years). All surviving patients (n = 10)
at time of last follow-up had resolution of hematologic disorder,
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Table 1
Patient Characteristics
1

2

3

4

5

Age at initial presentation, years

0.17

1

3.1

4.8

0.8

Gender

M

M

F

M

F

Race/Ethnicity

Hispanic

Caucasian

Caucasian

Caucasian

African American

Gene mutation

SAMD9 c.2471G>A; pR824Q

SAMD9 c.4690G>A;
p.G1564S

SAMD9 c.3406G>C;
p.E1136Q

SAMD9 c.3406G>C
p.E1136Q

SAMD9 c.2407 G>C;
p.E803Q

Family member with
same gene mutation

Parents negative

Parents negative

Patient no. 3 and 4 in this report,
a younger sibling and their
mother positive

Patient no. 3 and 4 in
this report, a younger
sibling and their
mother positive

Parents negative

MIRAGE syndrome features (SAMD9 cases)

Infections, restriction of growth, adrenal,
genital, enteropathy

MDS, infections, restriction of growth,
adrenal, enteropathy

MDS

MDS, genital

MDS, infections, restriction of growth,
enteropathy

Other clinical ﬁndings

Newborn Period: Born at 29 weeks, birth
weight 982 grams, mechanical ventilation.
Chronic lung disease of prematurity. Microcephaly, developmental delay, panhypopituitarism, laryngeal cleft, intussusception, FSGS

Newborn Period: Born at 34 weeks, birth
weight 1425 grams, no mechanical ventilation. Achalasia of esophagus, developmental delay





Newborn Period: Born at 36 weeks,
birth weight 1895 grams, no mechanical
ventilation. Staphylococcal sepsis with
respiratory failure. Developmental delay

Hematology

Thrombocytopenia followed by pancytopenia. Hypocellular marrow, megakaryocytic
hypoplasia

Pancytopenia. Hypocellular marrow,
reduced megakaryocytes and dysplasia

Thrombocytopenia. Hypocellular
marrow, trilineage dysplasia

Hypocellular marrow,
trilineage dysplasia,
refractory cytopenia of
childhood

Pancytopenia. Normocellular marrow,
megakaryocytic dysplasia

Chromosome 7

Somatic mosaic monosomy 7, somatic
mosaic chr. 7q deletion, UPD chr. 7

Somatic mosaic monosomy 7, somatic
mosaic 7q31 deletion, UPD chr. 7

Monosomy 7

Somatic mosaic monosomy 7

Somatic mosaic monosomy 7

Patient No.

6

7

8

9

10

Age at initial presentation, years

2.3

12.6

0.9

8.1

0.7

Gender

M

F

M

F

M

Race/Ethnicity

Caucasian

Hispanic

Hispanic

Caucasian

African American

Gene mutation

SAMD9 c.2318T>C; p.I773T

SAMD9L c.1877C>T; p.S626L

SAMD9L c.1877C>T;
p.S626L

SAMD9L c.3538T>C;
p.W1180R

SAMD9L c.4651 G>C;
p.V1551L

Family member with
same gene mutation

Mother negative, father unavailable

Patients no. 7 and 8 in this report are
nephews. Parents not tested. A maternal
aunt is positive

Patients no. 7 and 8 in this report
are nephews. Parents not tested.
A maternal aunt is positive

Parents not tested

Parents negative

MIRAGE syndrome features (SAMD9 cases)

MDS, infections, restriction of growth, adrenal, genital, enteropathy

N.A.

N.A.

N.A.

N.A.

Other clinical ﬁndings

Newborn Period: Born at 34 weeks, birth
weight 1853 grams, no mechanical ventilation. FSGS, short telomeres. microcephaly,
hypotelorism, strabismus, beaked nose,
reactive airway disease, warts





Hypogammagl
obulinemia

HLH. Sepsis

Hematology

Thrombocytopenia. Hypocellular marrow,
dysplastic megakaryocytes

Hypocellular marrow, dyserythropoiesis

Hypocellular marrow, dyserythropoiesis and
dysmegakaryopoiesis

Hypocellular marrow,
atypical
megakaryocytes

Pancytopenia. Hypocellular marrow,
dyserythropoiesis, dysgranulopoiesis

Chromosome 7

Mosaic chr. 7q deletion

Absence of heterozygosity chr. 7q
(myeloid)

Mosaic monosomy 7

Mosaic monosomy 7

Mosaic monosomy 7
(continued)
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Patient No.

Abbreviations: Chr. 7 (chromosome 7); FSGS (Focal sclerosing glomerulosclerosis); HCT (hematopoietic cell transplantation); HLH (hemophagocytic lymphohistiocytosis); MDS (myelodysplastic syndrome); MIRAGE syndrome (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy); and, UPD (uniparental disomy)

Chromosome 7

Mosaic monosomy 7, mosaic chr. 7q
deletion
Mosaic monosomy 7

Hematology

Eczema

Thrombocytopenia followed by pancytopenia. Normocellular marrow with dysplasia

Other clinical ﬁndings

Pancytopenia. Normocellular marrow
with megakaryocyte dysplasia

Eczema

MIRAGE syndrome features (SAMD9 cases)

N.A.
N.A.

Family member with
same gene mutation

Patients no. 11 and 12 in this report are
siblings. Father positive. Mother negative
Patients no. 11 and 12 in this report are siblings. Father positive. Mother negative

Gene mutation

Caucasian

SAMD9L c.2957G>A; p.R986H

Race/Ethnicity

SAMD9L c.2957G>A;
p.R986H

Caucasian

Gender

M
F

Age at initial presentation, years

12
11

1.6

Patient No.

Table 1 (Continued)

1.3
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had no chromosome 7 abnormalities, and sustained peripheral
blood donor chimerism (90% to 100%). All patients were thriving.
SAMD9 cases had varying degrees of developmental delays
(n = 6) and chronic kidney disease (n = 3). All patients with clinical characteristics of MIRAGE syndrome (n = 4) were short for
age, required supplemental feeds, and had persistent adrenal
insufﬁciency. In SAMD9L cases (n = 4), no clinical neurologic manifestations have been observed so far.
DISCUSSION
In this report, we describe transplant details and outcomes
in a series of patients with hematologic diseases associated
with SAMD9/SAMD9L germline mutations. We found that most
patients underwent transplantation for MDS with chromosome 7 abnormalities and received myeloablative conditioning
with HCT from nonsibling donor graft sources. Allogeneic HCT
led to successful resolution of MDS or marrow failure, with
sustained donor chimerism and excellent survival.
On review of literature, we found 10 other cases with
SAMD9 mutation who underwent HCT. A 4-year-old child with
MIRAGE syndrome and monosomy 7 MDS underwent transplantation with active AML and died of Epstein-Barr virusrelated lymphoproliferative disorder a year later [4]. Wilson
and colleagues [21] reported a patient with MIRAGE syndrome
who underwent reduced-intensity conditioning and unrelated
donor HCT that led to resolution of monosomy 7 MDS. Sarthy
et al. [14] described a patient with marrow failure and another
patient with MDS who had severe MIRAGE phenotypes and
underwent HCT after reduced-intensity conditioning. Comorbidities, including enteropathy, electrolyte imbalances, adrenal
crises, bacteremia, and lung disease, signiﬁcantly led to a complicated transplant course and ultimately death in both cases.
Although transplant details in 6 other cases are limited, 1
patient without the MIRAGE phenotype died of unknown
cause, and 5 were surviving following HCT [7,10]. There were
4 cases of MIRAGE syndrome in our series. Before transplant, 3
of 4 cases had chronic diarrhea, malnutrition, and adrenal
insufﬁciency. Post-HCT, we observed severe gastrointestinal
ﬂuid losses, electrolyte imbalance, and acute dehydration in
these 3 cases. Whether such dramatic stool losses without an
infectious etiology were secretory and whether autonomic
instability could have contributed are unknown. Patients also
experienced temperature and blood pressure instability, respiratory distress, and acute renal dysfunction.
Several of these medical issues are similar to those reported
in the report by Sarthy et al. [14]. Despite a complicated acute
transplant course, all 4 patients with MIRAGE syndrome in our
series survived.
We observed a high rate of ongoing medical issues in
MIRAGE syndrome transplant survivors. These include adrenocortical insufﬁciency, diarrhea, need for supplemental nutrition, and developmental delays. Patients with pre-existing
lung disease and nephropathy continue to have these issues
following HCT. Most of these issues are related to pre-existing
MIRAGE syndrome manifestations. The transplant survivor
reported by Wilson et al. [21] had ongoing medical issues of
adrenocortical insufﬁciency, growth and developmental
delays, and chronic lung and chronic kidney diseases.
In this series, all 6 SAMD9L patients had cytopenias and
MDS with chromosome 7 abnormalities. We did not observe
ataxia, incoordination, or other neurologic manifestations
before or following transplant. On review of the literature, we
found 11 additional cases of patients with SAMD9L mutations
who had undergone HCT [5,7,11]. Although transplant details
are limited, 2 patients died of complications (cerebral
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Table 2
Pathogenicity Assessment of Observed SAMD9 and SAMD9L Variants
1

2

3

4

5

Gene and Variant

SAMD9. Heterozygous c.2471G>A
(p.Arg824Gln)

SAMD9. Heterozygous c.4690G>A
(p.G1564S)

SAMD9. Heterozygous c.3406G>C
(p.E1136Q)

SAMD9. Heterozygous c.3406G>C
(p.E1136Q)

SAMD9. Heterozygous
c.2407 G>C (p.E803Q)

Method of genetic
diagnosis

WES conﬁrmed by Sanger sequencing

WES conﬁrmed by Sanger
sequencing

WES and WGS, targeted Sanger
sequencing of parent

WES and WGS, targeted Sanger
sequencing of parent

WES conﬁrmed by
Sanger sequencing

SAMD9 / SAMD9L variant: De novo status

De novo (parentage conﬁrmed)

Since parents negative, this should
be de novo, but parentage not
conﬁrmed

Not de novo

Not de novo

De novo (parentage
conﬁrmed)

Germline source

Kidney



Sorted lymphocytes

Sorted lymphocytes



Family tested for the
same variant

Sibling donor was not tested prior to BMT
since the SAMD9 variant was discovered in
the recipient afterwards. Parents subsequently tested and were negative.

Parents negative

Patient no. 3 and 4 in this report, a
younger sibling and their mother
positive. The younger sibling had
transient thrombocytopenia at birth
requiring platelet transfusion.

Patient no. 3 and 4 in this report, a
younger sibling and their mother
positive. The younger sibling had
transient thrombocytopenia at birth
requiring platelet transfusion.

Parents negative

ACMG* classiﬁcation

Pathogenic

Likely Pathogenic

VUS (Potentially Pathogenicy)

VUS (Potentially Pathogenicy)

Likely Pathogenic

How pathogenicity was
ascribed

PS2 – de novo, parentage conﬁrmed
PS3 – functional study supports damaging
effect
PM2 – absent from controls

PM2 – absent from controls
PM6 – assumed de novo
PP3 – in silico prediction: deleterious
PP4 – UPD7 together with MIRAGE
features

PS3 – functional study supports
damaging effect
PM2 – absent from controls
BS4 – lack of segregation in family
members

PS3 – functional study supports
damaging effect
PM2 – absent from controls
BS4 – lack of segregation in family
members

PS2 – de novo, parentage
conﬁrmed
PM2 – absent from
controls

References

Jeffries et al. [18]

Not found via literature search

Schwartz et al, [8] (Leukemia),
Schwartz et al, [13] (Nat Comm)

Schwartz et al, [8] (Leukemia),
Schwartz et al, [13] (Nat Comm)

Not found via literature
search

Patient No.

6

7

8

9

10

Gene and Variant

SAMD9. Heterozygous c.2318T>C (p.I773T)

SAMD9L. Heterozygous c.1877C>T;
p.S626L

SAMD9L. Heterozygous c.1877C>T
(p.S626L)

SAMD9L. Heterozygous c.3538T>C
(p.W1180R)

SAMD9L. Heterozygous
c.4651 G>C
(p.V1551L)

Method of genetic
diagnosis

WES conﬁrmed by Sanger sequencing

WES conﬁrmed by Sanger
sequencing

WES conﬁrmed by Sanger
sequencing

WES conﬁrmed by Sanger
sequencing

WES conﬁrmed by
Sanger sequencing

SAMD9 / SAMD9L variant: De novo status

De novo status not known since dad not
tested

Parents not tested. Aunt has the
same variant.
De novo status not known.

Parents not tested. Aunt has the
same variant. De novo status not
known.

Parents not tested. De novo status
not known.

De novo (parentage
conﬁrmed)

Germline source









Skin ﬁbroblasts

Family tested for the
same variant

Mother tested and was negative. Dad
unavailable for testing

Patients no. 7 and 8 in this report are
nephews. A maternal aunt with cytopenias and conﬁrmed SAMD9L mutation (parents not tested for SAMD9/
SAMD9L), brother with cytopenias
(not tested).

Patients no. 7 and 8 in this report
are nephews. A maternal aunt with
cytopenias and conﬁrmed SAMD9L
mutation (parents not tested for
SAMD9/SAMD9L), brother with cytopenias (not tested).

Parents not tested

Parents negative

ACMG* classiﬁcation

VUS

Likely Pathogenic

Likely Pathogenic

Likely Pathogenic

Pathogenic

How pathogenicity was
ascribed

PM2 - absent from controls
PP4 – subclonal 7q deletion together with
MIRAGE features

PS3 – functional study supports damaging effect
PM2 – absent from controls
PP1 – segregates with affected family
members

PS3 – functional study supports
damaging effect
PM2 – absent from controls
PP1 – segregates with affected family members

PS3 – functional study supports
damaging effect
PM2 – absent from controls

PS2 – de novo
PS3 – functional study
supports damaging
effect
PM2 – absent from
controls

References

Perisa et al, [17]

Schwartz et al, [8] (Nat Comm)

Schwartz et al, [8] (Nat Comm)

Schwartz et al, [8] (Nat Comm)

Ortolano et al, [19]
(continued)
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Patient No.

Table 2 (Continued)
Patient No.

11

12

Gene and Variant

SAMD9L. Heterozygous c.2957G>A (p.R986H)

SAMD9L. Heterozygous c.2957G>A
(p.R986H)

Method of genetic
diagnosis

Sanger sequencing of peripheral blood. Conﬁrmed by Sanger sequencing of hair follicles

Targeted NGS. Conﬁrmed by Sanger
sequencing of hair follicles

SAMD9 / SAMD9L variant: De novo status

Not de novo

Not de novo

Germline source

Hair follicles

Hair follicles

Family tested for the
same variant

Patients no. 11 and 12 in this report are siblings. Father positive. Mother negative.

Patients no. 11 and 12 in this report
are siblings. Father positive. Mother
negative.

Likely Pathogenic

Likely Pathogenic

How pathogenicity was
ascribed

PS3 – functional study supports damaging
effect
PM5 – another variant
(p.R986C) at the same
position is pathogenic

PS3 – functional study supports damaging effect
PM5 – another variant
(p.R986C) at the same
position is pathogenic

References

Tesi et al, [5]; Bluteau et al, [7]; Wong et al,
[12]

Tesi et al, [5]; Bluteau et al, [7];
Wong et al, [12]

Abbreviations: WES indicates whole exome sequencing; WGS, whole genome sequencing; BMT, blood and marrow transplantation; ACMG, American College of Medical Genetics, and VUS, variant of unknown signiﬁcance; NGS, Next
generation sequencing.
* Each pathogenic criterion was weighted as very strong (PVS1), strong (PS1–4); moderate (PM1–6) or supporting (PP1–5) and each benign criterion was weighted as stand-alone (BA1), strong (BS1–4) or supporting (BP1–6). From
Richards et al, [20].
y
The SAMD9 variant c.3406G>C (p.E1136Q) was classiﬁed as a VUS using strict ACMG criteria. We believe this variant is pathogenic based on well-established functional data from two separate experimental studies showing that it
has a deleterious effect on cells. The younger sibling of the patients above also carries the variant and had transient neonatal thrombocytopenia requiring transfusion. However, the mother of these patients carries the variant as well and
presently lacks an apparent phenotype. Whether she was transiently affected in the past is unknown, but this is possible as somatic revertant mosaicism is a known associated phenomenon with SAMD9/SAMD9L variants. Other potential
mechanisms that could account for the lack of phenotypic segregation include monoallelic gene expression, incomplete penetrance, or variable expressivity. We feel this is important to note for clinical reasons in case this variant is
observed in another patient.
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ACMG* classiﬁcation
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Table 3
Transplant Characteristics and Outcomes
1

2

3

4

5

Gene involved

SAMD9 (MIRAGE syndrome)

SAMD9 (MIRAGE syndrome)

SAMD9

SAMD9

SAMD9 (MIRAGE syndrome)

Age at HCT, years

6.7

1.4

3.3

5

1.2

Interval from diagnosis
to HCT, years

6.5

0.4

0.2

0.2

0.4

Indication for HCT

Presumed congenital amegakaryocytic
thrombocytopenia

MDS

MDS

MDS

MDS

Signiﬁcant pretransplant
issues

Secretory diarrhea, adrenocortical
insufﬁciency, lung disease, CKD, failure
to thrive

Esophageal achalasia, gastroesophageal reﬂux, diarrhea, failure to thrive





Diarrhea. Failure to thrive.

Donor type

HLA-identical sibling, female, bone
marrow

Unrelated, 10/10 allele match, male,
bone marrow

Unrelated, 8/8 allele match,
female, bone marrow

Unrelated, 8/8 allele match,
male, bone marrow

Father, 5/10 allele match, bone
marrow

Conditioning regimen;
GVHD prophylaxis

Flu/Cy/ATG; Tac/MMF

Bu/Flu/ATG; Tac/Mtx

Bu/Cy/ATG; CsA/Mtx

Bu/Cy/ATG; CsA/Mtx

Bu/Flu; posttransplant Cy, Tac/MMF

Conditioning intensity
(MA / RIC)

RIC

MA

MA

MA

MA

Neutrophil engraftment,
days+

13

12

16

19

14

Platelet engraftment,
days+

16

30

14

15

40

Posttransplant course

Temperature & blood pressure instability, electrolyte imbalance, dehydration,
hypoxia

TMA, recurrent pericardial effusions,
hypoxia

VOD of liver

Pericardial effusion

TMA, pericardial effusion, VOD of
liver

Intensive care

Severe hypertension

No

Respiratory distress, did not
require intubation

Respiratory distress,
required intubation

Respiratory failure, did not require
intubation

Acute GVHD / Chronic
GVHD

No / No

No / Yes

No / No

No / No

No / No

Chimerism

99% donor

100% donor

100% donor

99% donor

100% donor

Post-HCT hematologic
outcome

Normal blood counts, no monosomy 7

Normal blood counts, no monosomy
7, resolution of MDS

Resolution of MDS, no chr. 7
ﬁnding

Resolution of MDS, no chr. 7
ﬁndings

Normal blood counts, no monosomy
7, resolution of MDS

Survival status

Alive; 2.4 y post-HCT

Alive; 3.8 y post-HCT

Alive; 3.2 y post-HCT

Alive; 3 y post-HCT

Alive; 1.4 y post-HCT

Current health status

Secretory diarrhea, enteral feeds, low
weight and height, thriving, developmental delay, CKD, hypertension, adrenal insufﬁciency

Recurrent aspiration pneumonias,
chronic lung disease, malnutrition,
diarrhea, developmental delay,
thriving, adrenal insufﬁciency

School performance issues

Learning disabilities

Supplemental feeds, hypoglycemia
episodes, diarrhea, low weight and
height, thriving, developmentally
delay
(continued)
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Patient No.

Table 3 (Continued)
Patient No.

6

7

8

9

10

Gene involved

SAMD9 (MIRAGE syndrome)

SAMD9L

SAMD9L

SAMD9L

SAMD9L

Age at HCT, years

7.8

12.8

2.3

8.3

2

Interval from diagnosis
to HCT, years

5.5

0.2

1.4

0.2

1.3

MDS

Presumed dyskeratosis congenita

MDS

MDS

MDS

Signiﬁcant pretransplant
issues

Hypertension, chronic kidney disease,
asthma

Obesity (BMI 34, >97th percentile
for age)

Obesity (BMI 27, >97th percentile for age)



HLH therapy. E. coli sepsis, pancolitis, ecthyma gangrenosum, aspergillus and candida sepsis

Donor type

Unrelated, 10/10 allele match, male,
bone marrow

Unrelated double cord blood, male
(5/6 allele match), female (5/6 allele
match)

Unrelated cord blood, 6/6
allele match, female

HLA-identical sibling,
female, bone marrow

Unrelated, 9/10 allele match, bone
marrow

Conditioning regimen;
GVHD prophylaxis

Flu/Mel/Alemtuzumab; Tac/MMF

Flu/Mel/Alemtuzumab; Tac/MMF

Flu/Cy/TBI; CsA/MMF

Cy/TBI/Ara-C

Bu/Cy/ATG

Conditioning intensity
(MA / RIC)

RIC

RIC

MA

MA

MA

Neutrophil engraftment,
days+

19

No

13

17

18

Platelet engraftment,
days+

19

No

12

31

No

Posttransplant course

Blood pressure instability, electrolyte
imbalance, fevers, hypoxia

Restrictive lung disease

Parainﬂuenza with respiratory failure, renal
dysfunction

Culture negative sepsis,
bleeding gastric ulcer, hemorrhagic cystitis

Coronavirus respiratory tract infection, VOD of liver with respiratory
failure, deﬁbrotide, diffuse alveolar
hemorrhage

Intensive care

No

No

Respiratory failure

Systemic inﬂammatory
response syndrome

Respiratory failure, required
intubation

Acute GVHD / Chronic
GVHD

No / No

No / No

Yes (Grade II, GI, resolved)/
No

No / No

Not evaluable / Not evaluable

Chimerism

98% donor

0% donor

99% donor

100% donor

Not done

Post-HCT hematologic
outcome

Normal blood counts

Graft failure

Resolution of MDS, no chr. 7
ﬁnding

Resolution of MDS, no chr. 7
ﬁnding

Neutrophil engraftment. Bone marrow not assessed

Survival status

Alive; 4.1 y post-HCT

Died of refractory AML; 1.1 y postHCT

Alive; 2.3 y post-HCT

Alive; 14.7 y post-HCT

Died at day +23 post-HCT from complications related to VOD of liver

Current health status

Adrenal insufﬁciency, diarrhea, hypotension, CKD, urethrocutaneous ﬁstula,
developmental delay, thriving

N.A.

CKD

Doing well

N.A.
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Indication for HCT

(continued)
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Table 3 (Continued)
11

12

Gene involved

SAMD9L

SAMD9L

Age at HCT, years

2.1

1.8

Interval from diagnosis
to HCT, years

0.5

0.5

Indication for HCT

MDS

MDS

Signiﬁcant pretransplant
issues

Otitis media, croup, roseola

Alpha hemolytic streptococcal sepsis

Donor type

Unrelated, 10/10 allele match, female,
bone marrow

Unrelated, 10/10 allele match,
female, bone marrow

Conditioning regimen;
GVHD prophylaxis

Bu/Cy; Tac/Mtx

Bu/Cy; Tac/Mtx

Conditioning intensity
(MA / RIC)

MA

MA

Neutrophil engraftment,
days+

19

9

Platelet engraftment,
days+

17

12

Posttransplant course

Uneventful

VOD of liver, hemolysis,
coagulopathy

Intensive care

No

VOD

Acute GVHD / Chronic
GVHD

Yes (Grade II, skin, gut, resolved) / Yes
skin, mild

No / No

Chimerism

100% donor

100% donor

Post-HCT hematologic
outcome

Normal blood counts, no monosomy 7,
resolution of MDS

Normal blood counts, no monosomy
7, resolution of MDS

Survival status

Alive; 5.3 y post-HCT

Alive; 1.3 y post-HCT

Current health status

Doing well

Doing well

Abbreviations: ATG (anti-thymocyte globulin); Ara-C (cytosine arabinoside); BU (busulfan); BMI (body mass index); Chr. 7 (chromosome 7); CKD (chronic kidney disease); Cy (cyclophosphamide); CsA (cyclosporine A); GI (gastrointestinal); Flu (ﬂudarabine); HLH (hemophagocytic lymphohistiocytosis); MA (myeloablative); MDS (myelodysplastic syndrome); Mel (melphalan); MIRAGE syndrome (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy); MMF (mycophenolate mofetil); Mtx (methotrexate); N.E. (not evaluable); RIC (reduced intensity conditioning); Tac (tacrolimus); TBI (total body irradiation); TMA (thrombotic microangiopathy); and
VOD (veno-occlusive disease)
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Patient No.
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Table 4
Summary of Available Clinical Data on Immune Reconstitution
Patient No.
Characteristic

1

2

5

6

3

4

8

11

12

Gene mutation

SAMD9

SAMD9

SAMD9

SAMD9

SAMD9

SAMD9

SAMD9L

SAMD9L

SAMD9L

MIRAGE phenotype

Yes

Yes

Yes

Yes

No

No

No

No

No

570

678

470

252

924

546

288

NA

1512

1970

1000

1320

864

2368

240

826

NA

112

ALC per cumm

2080

1307

1650

ND

ND

1125

410

NA

370

CD3 per cumm

375

891

ND

ND

ND

ND

ND

NA

NA

CD4 per cumm

250

369

ND

ND

ND

ND

ND

NA

NA

CD8 per cumm

83

486

ND

ND

ND

ND

ND

NA

NA

NK cells per cumm

520

167

ND

ND

ND

ND

ND

NA

NA

CD19 per cumm

1145

249

ND

ND

ND

ND

ND

NA

NA

Serum IgG, mg/dL

123

1120

519

822

ND

395

ND

NA

NA

ALC per cumm

2500

840

4630

1254

ND

544

935

980

981

CD3 per cumm

1150

726

2224

390

ND

ND

ND

ND

451

CD4 per cumm

600

308

1308

277

ND

ND

ND

ND

216

CD8 per cumm

500

377

828

86

ND

ND

ND

ND

212

NK cells per cumm

900

114

916

193

ND

ND

ND

ND

193

CD19 per cumm

450

0

1264

662

ND

ND

ND

ND

337

Serum IgG, mg/dL

346

254

915

752

522

218

ND

389

521

ALC per cumm

6100

1801

8200

1938

ND

770

2220

1490

4070

CD3 per cumm

3841

999

6232

1212

ND

ND

ND

1356

2426

CD4 per cumm

1829

495

3526

737

ND

ND

ND

374

1548

Lymphocyte enumeration
1 month post-HCT
ALC per cumm
2 months post-HCT
ALC per cumm
3 months post-HCT

6 months post-HCT

12 months post-HCT

CD8 per cumm

1890

459

2460

362

ND

ND

ND

884

829

NK cells per cumm

549

185

656

178

ND

ND

ND

97

422

CD19 per cumm

1646

617

1148

Serum IgG, mg/dL

759

623

502

ND

ND

ND

127

1121

371

ND

300

841

351

NA

Patient 1 (SAMD9 with MIRAGE): Protein-losing enteropathy. Intravenous immunoglobulin (IVIG) infusions. Patient 2 (SAMD9 with MIRAGE): Chronic diarrhea.
Patient 3 (SAMD9 without MIRAGE): Lymphocyte enumeration 3 years post-HCT, ALC 4555, CD3 3160, CD4 1330, CD8 1610, NK cells 480, CD19 740, all in per cumm.
Patient 4 (SAMD9 without MIRAGE): Lymphocyte enumeration 3 years post-HCT, ALC 3700, CD3 2530, CD4 1090, CD8 1140, NK cells 400, CD19 770, all in per cumm.
Patient 5 (SAMD9 with MIRAGE): IVIG infusions monthly until 1 year post-HCT. Patient 6 (SAMD9 with MIRAGE): IVIG infusions monthly until 6 months post-HCT.
Patient 7 (SAMD9L): Not included in the table. ALC 286 on day +60. Graft failure. Patient 8 (SAMD9L): Lymphocyte enumeration 5 years post-HCT, ALC 3600, CD3
2630, CD4 1200, CD8 1310, NK cells 120, CD19 810, all in per cumm. Patient 9 (SAMD9L): Not included in the table. Underwent HCT 14 years ago. Data not available.
Patient 10 (SAMD9L): No data. The patient died of transplant complications on day +23. Patient 11 (SAMD9L): Intermittent IVIG infusions. Patient 12 (SAMD9L): Intermittent IVIG infusions.
ALC indicates absolute lymphocyte count; ND, not done; NK, natural killer; IgG, immunoglobulin G.

hemorrhage and infection, 1 each), 1 had unknown survival
status, and 8 were alive. Of the surviving patients, 1 had pulmonary ﬁbrosis, and 3 had neurologic issues.
Mutations in SAMD9 and SAMD9L add to a growing list of
recently described heritable conditions associated with cytopenias,
marrow failure, MDS, and AML [1,7,8]. Although these patients can
be managed symptomatically with transfusions and treatment of
infections, the only curative treatment is with allogeneic HCT.
Indications and timing of HCT in these patients are not
straightforward because marrow cells can undergo somatic
genetic correction events and spontaneous blood count recovery
[4,8,12,22]. In our series, there was an interval of several years
from initial presentation to development of bone marrow failure
or MDS in 2 cases. Most patients in our series underwent transplantation for MDS with transfusion dependence, and a diagnosis
of SAMD9/SAMD9L was made retrospectively from archived specimens. Affected siblings of patients who underwent transplantation have been followed without transplant; however, these are
anecdotal case reports, and long-term data are needed [8,11].

Patients who have relatively stable blood counts and do not
show signs of development of MDS or AML may continue to be
closely observed. However, in our view, patients who develop
signiﬁcant marrow failure (including if clinically symptomatic
with infections, anemia, bleeding, and/or transfusion dependence), meet morphologic criteria of MDS, develop monosomy
7 or 7q-, or develop other cytogenetic abnormalities associated
with myeloid malignancies should be evaluated for allogeneic
HCT. Any potential family donors must undergo genetic evaluation for SAMD9/SAMD9L mutation as well.
In conclusion, in this small series of patients, we found
that most patients with SAMD9/SAMD9L mutations tolerated
transplant conditioning, with a high rate of engraftment and
resolution of MDS or marrow failure. Clinically signiﬁcant
comorbidities were common in MIRAGE syndrome cases
and contributed to unique adverse events in the acute posttransplant phase. These patients continue to require ongoing management and multispecialty care for syndromerelated nonhematologic manifestations.
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More data are needed to deﬁne timing of HCT in SAMD9/
SAMD9L patients and further reﬁne conditioning regimens as
well as management of patients with signiﬁcant syndromerelated comorbidities. National and international transplant
registries should be queried to examine reported outcomes in
larger patient cohorts. Finally, long-term follow-up and care
guidelines are needed for the survivors.
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